End Stage Renal Disease (ESRD) Drug Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The End Stage Renal Disease (ESRD) Drug Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current End Stage Renal Disease (ESRD) Drug Market Size and Its Estimated Growth Rate?
The market size for end-stage renal disease (ESRD) medications has witnessed a rapid upsurge in recent years. The market is projected to expand from a value of $131.41 billion in 2024 to $149.88 billion in 2025, representing a compound annual growth rate (CAGR) of 14.1%. Factors contributing to the growth during the historic period include an increase in ESRD diagnosis, rise in elderly population, better accessibility to healthcare services, government support and policies, and an increase in the acceptance of renal replacement therapies.

Predictions indicate a swift expansion in the market size for end stage renal disease (ESRD) drugs in the upcoming years, with an anticipated value of $268.44 billion in 2029, showcasing a compound annual growth rate (CAGR) of 15.7%. This predicted growth during the forecast period is largely attributed to the advent of novel therapies and drug innovations, hikes in healthcare spending, an escalating worldwide prevalence of chronic kidney diseases, personalized treatment strategies, supportive regulatory frameworks and swift approvals. Key trends expected in this forecast period consist of a rising occurrence of end stage renal disease, breakthroughs in treatment procedures, an increased focus on precision medicine, progress in combination therapies, and the incorporation of technology in healthcare.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

What Are the High-Growth Segments in the End Stage Renal Disease (ESRD) Drug Market?
The end stage renal disease (ESRD) drug market covered in this report is segmented -

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Key Drivers Are Expected to Influence Future End Stage Renal Disease (ESRD) Drug Market Growth?
The escalation in obesity and diabetes cases is anticipated to spur the development of the end-stage renal disease (ESRD) drug market. Obesity is characterized by an unusual or excessive accumulation of fat that presents a health risk, while diabetes is a long-term condition occurring when the pancreas fails to produce adequate insulin or when the body can't effectively use the insulin it generates. Controlling fluid and electrolyte levels, blood pressure, and waste product expulsion via dialysis in renal disease patients can boost overall health and wellness, potentially leading to weight loss and enhanced blood sugar management. For example, World Obesity, a US-based organization representing national and regional associations committed to studying and managing obesity, reported in March 2022 that the count of obese individuals is projected to ascend to 892 million in 2025 and subsequently to 1,025 million by 2030. In addition, in February 2023, the National Health Service, a UK-based publicly funded healthcare system, estimated that by 2030, the population of people in the UK with diabetes could expand to 5.5 million, affecting roughly 9% of the population. Thus, the growing incidence of obesity and diabetes will fuel the end-stage renal disease (ESRD) drug market.

Which Companies Hold the Largest Share Across Different End Stage Renal Disease (ESRD) Drug Market Segments?
Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

What Trends Are Driving Growth in The End Stage Renal Disease (ESRD) Drug Market?
Innovative product development is a significant trend driving the popularity of the market for end-stage renal disease (ESRD) drugs. Top companies in this market are concentrating their efforts on the creation of cutting-edge solutions to maintain their competitive edge. Specifically, GlaxoSmithKline PLC, a pharmaceutical and biotechnology firm from the UK, stated in April 2022 that the US Food and Drug Administration (FDA) approved their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the potential treatment of anemia in chronic kidney disease patients (CKD). This innovative product is grounded in the unique and Nobel Prize-awarded scientific research, demonstrating how cells detect and adapt to the levels of available oxygen.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Are the Emerging Geographies for The End Stage Renal Disease (ESRD) Drug Market Growth?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the End Stage Renal Disease (ESRD) Drug Market?
2. What is the CAGR expected in the End Stage Renal Disease (ESRD) Drug Market?
3. What Are the Key Innovations Transforming the End Stage Renal Disease (ESRD) Drug Industry?
4. Which Region Is Leading the End Stage Renal Disease (ESRD) Drug Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.